James D Chalmers

List of Publications by Year
in descending order

349 papers	17,666 citations	13099 68 h-index	19190 118 g-index
371 all docs	371 docs citations	371 times ranked	12809 citing authors

#	Article	IF	Citations
1	European Respiratory Society guidelines for the management of adult bronchiectasis. European Respiratory Journal, 2017, 50, 1700629.	6.7	788
2	The Bronchiectasis Severity Index. An International Derivation and Validation Study. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 576-585.	5.6	747
3	Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals. Annals of the American Thoracic Society, 2019, 16, 22-28.	3.2	458
4	Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respiratory Medicine,the, 2021, 9, 1275-1287.	10.7	394
5	Short- and Long-Term Antibiotic Treatment Reduces Airway and Systemic Inflammation in Nonâ€“Cystic Fibrosis Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 657-665.	5.6	330
6	C-Reactive Protein Is an Independent Predictor of Severity in Community-acquired Pneumonia. American Journal of Medicine, 2008, 121, 219-225.	1.5	303
7	British Thoracic Society Guideline for bronchiectasis in adults. Thorax, 2019, 74, 1-69.	5.6	291
8	A Randomized Controlled Trial of Nebulized Gentamicin in Nonâ€“Cystic Fibrosis Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 491-499.	5.6	264
9	Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax, 2010, 65, 878-883.	5.6	262
10	A Comprehensive Analysis of the Impact ofPseudomonas aeruginosaColonisation on Prognosis in Adult Bronchiectasis. Annals of the American Thoracic Society, 2015, 12, 1602-11.	3.2	258
11	Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. European Respiratory Journal, 2017, 49, 1700051.	6.7	253
12	Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet, The, 2018, 392, 880-890.	13.7	247
13	Etiology of Nonâ€“Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity. Annals of the American Thoracic Society, 2015, 12, 1764-1770.	3.2	233
14	Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1384-1393.	5.6	232
15	Epidemiology, Antibiotic Therapy, and Clinical Outcomes in Health Care-Associated Pneumonia: A UK Cohort Study. Clinical Infectious Diseases, 2011, 53, 107-113.	5.8	231
16	Pneumonia. Nature Reviews Disease Primers, 2021, 7, 25.	30.5	230
17	Healthcare-Associated Pneumonia Does Not Accurately Identify Potentially Resistant Pathogens: A Systematic Review and Meta-Analysis. Clinical Infectious Diseases, 2014, 58, 330-339.	5.8	224
18	Management of bronchiectasis in adults. European Respiratory Journal, 2015, 45, 1446-1462.	6.7	220

#	Article	IF	Citations
19	Clinical phenotypes in adult patients with bronchiectasis. European Respiratory Journal, 2016, 47, 1113-1122.	6.7	215
20	Characterization of the â€œFrequent Exacerbator Phenotypeâ€•in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1410-1420.	5.6	215
21	Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. Lancet Respiratory Medicine,the, 2016, 4, 969-979.	10.7	210
22	Neutrophil extracellular traps are associated with disease severity and microbiota diversity in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2018, 141, 117-127.	2.9	207
23	The type VII secretion system of Staphylococcus aureus secretes a nuclease toxin that targets competitor bacteria. Nature Microbiology, 2017, 2, 16183.	13.3	206
24	Predictors of Mortality in Hospitalized Adults with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis. Annals of the American Thoracic Society, 2013, 10, 81-89.	3.2	203
25	The microbiome in respiratory medicine: current challenges and future perspectives. European Respiratory Journal, 2017, 49, 1602086.	6.7	194
26	Development and Reporting of Prediction Models: Guidance for Authors From Editors of Respiratory, Sleep, and Critical Care Journals. Critical Care Medicine, 2020, 48, 623-633.	0.9	188
27	Bronchiectasis. Nature Reviews Disease Primers, 2018, 4, 45.	30.5	181
28	Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration. European Respiratory Journal, 2016, 48, 632-647.	6.7	170
29	Prior Statin Use Is Associated with Improved Outcomes in Community-acquired Pneumonia. American Journal of Medicine, 2008, 121, 1002-1007.e1.	1.5	159
30	Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. New England Journal of Medicine, 2020, 383, 2127-2137.	27.0	158
31	Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. European Respiratory Journal, 2021, 57, 2100048.	6.7	152
32	The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. European Respiratory Journal, 2018, 51, 1701953.	6.7	150
33	Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Molecular Immunology, 2013, 55, 27-34.	2.2	149
34	Bronchiectasis: new therapies and new perspectives. Lancet Respiratory Medicine,the, 2018, 6, 715-726.	10.7	147
35	Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis. BMC Pulmonary Medicine, 2018, 18, 83.	2.0	143
36	The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions. European Respiratory Journal, 2018, 52, 1800328.	6.7	138

#	Article	IF	Citations
37	Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Medicine, 2011, 37, 1409-1420.	8.2	134
38	Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. Lancet Respiratory Medicine,the, 2019, 7, 213-226.	10.7	134
39	The EMBARC European Bronchiectasis Registry: protocol for an international observational study. ERJ Open Research, 2016, 2, 00081-2015.	2.6	133
40	Validation of the Infectious Diseases Society of America/American Thoratic Society Minor Criteria for Intensive Care Unit Admission in Community-Acquired Pneumonia Patients Without Major Criteria or Contraindications to Intensive Care Unit Care. Clinical Infectious Diseases, 2011, 53, 503-511.	5.8	131
41	Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective: TableÂ1. Thorax, 2013, 68, 997-999.	5.6	129
42	Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. European Respiratory Journal, 2018, 52, 1701190.	6.7	122
43	Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax, 2013, 68, 39-47.	5.6	121
44	Severe Pneumococcal Pneumonia Causes Acute Cardiac Toxicity and Subsequent Cardiac Remodeling. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 609-620.	5.6	120
45	Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. The Lancet Global Health, 2019, 7, e1269-e1279.	6.3	116
46	Immunological corollary of the pulmonary mycobiome in bronchiectasis: the CAMEB study. European Respiratory Journal, 2018, 52, 1800766.	6.7	105
47	Treatment of Community-Acquired Pneumonia in Immunocompromised Adults. Chest, 2020, 158, 1896-1911.	0.8	105
48	Integrative microbiomics in bronchiectasis exacerbations. Nature Medicine, 2021, 27, 688-699.	30.7	105
49	Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 845-854.	10.7	104
50	The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2021, 147, 158-167.	2.9	102
51	Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ, The, 2013, 346, f1235-f1235.	6.0	101
52	Challenges in severe community-acquired pneumonia: a point-of-view review. Intensive Care Medicine, 2019, 45, 159-171.	8.2	100
53	Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy?. Thorax, 2014, 69, 609-615.	5.6	99
54	Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study. Lancet Respiratory Medicine,the, 2021, 9, 873-884.	10.7	99

#	Article	IF	Citations
55	Risk Factors for Aspiration in Community-acquired Pneumonia: Analysis of a Hospitalized UK Cohort. American Journal of Medicine, 2013, 126, 995-1001.	1.5	95
56	European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis. European Respiratory Journal, 2021, 58, 2002990.	6.7	95
57	Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review. Respiratory Medicine, 2018, 137, 6-13.	2.9	90
58	Community-acquired pneumonia related to intracellular pathogens. Intensive Care Medicine, 2016, 42, 1374-1386.	8.2	85
59	Heterogeneity in <scp>ess</scp> transcriptional organization and variable contribution of the <scp>Ess</scp>/Type <scp>VII</scp> protein secretion system to virulence across closely related <scp>S</scp>taphylocccus aureus strains. Molecular Microbiology, 2014, 93, 928-943.	2.5	84
60	Treatable traits in bronchiectasis. European Respiratory Journal, 2018, 52, 1801269.	6.7	84
61	The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease. Lancet Respiratory Medicine,the, 2021, 9, 1467-1478.	10.7	84
62	Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). European Respiratory Review, 2020, 29, 200287.	7.1	82
63	Bronchiectasis Rheumatoid Overlap Syndrome Is an Independent RiskÂFactor for Mortality in Patients WithÂBronchiectasis. Chest, 2017, 151, 1247-1254.	0.8	81
64	Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. European Respiratory Journal, 2020, 55, 2000351.	6.7	81
65	Human L-Ficolin (Ficolin-2) and Its Clinical Significance. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-10.	3.0	77
66	The role of neutrophils in cystic fibrosis. Current Opinion in Hematology, 2014, 21, 16-22.	2.5	76
67	Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study. Lancet Respiratory Medicine,the, 2013, 1, 224-232.	10.7	75
68	The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 855-869.	10.7	75
69	Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial. Lancet Respiratory Medicine,the, 2014, 2, 455-463.	10.7	74
70	Characterizing Non-Tuberculous Mycobacteria Infection in Bronchiectasis. International Journal of Molecular Sciences, 2016, 17, 1913.	4.1	70
71	Airway Bacterial Load and Inhaled Antibiotic Response in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 33-41.	5.6	70
72	Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. Lancet Respiratory Medicine,the, 2022, 10, 298-306.	10.7	70

#	Article	IF	Citations
73	Statins in community acquired pneumonia: Evidence from experimental and clinical studies. Respiratory Medicine, 2010, 104, 1081-1091.	2.9	69
74	Impact of mannose-binding lectin insufficiency on the course of cystic fibrosis: A review and meta-analysis. Glycobiology, 2011, 21, 271-282.	2.5	69
75	The microbiome in bronchiectasis. European Respiratory Review, 2019, 28, 190048.	7.1	68
76	Predicting the Need for Mechanical Ventilation and/or Inotropic Support for Young Adults Admitted to the Hospital with Communityâ€Acquired Pneumonia. Clinical Infectious Diseases, 2008, 47, 1571-1574.	5.8	67
77	Characterization of Eosinophilic Bronchiectasis: A European Multicohort Study. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 894-902.	5.6	67
78	Incidence and Prognostic Implications of Acute Kidney Injury on Admission in Patients With Community-Acquired Pneumonia. Chest, 2010, 138, 825-832.	0.8	65
79	Obesity is associated with improved survival in community-acquired pneumonia. European Respiratory Journal, 2013, 42, 180-187.	6.7	65
80	Simplification of the IDSA/ATS criteria for severe CAP using meta-analysis and observational data. European Respiratory Journal, 2014, 43, 842-851.	6.7	63
81	Standardised classification of the aetiology of bronchiectasis using an objective algorithm. European Respiratory Journal, 2017, 50, 1701289.	6.7	63
82	The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study. Lancet Respiratory Medicine,the, 2021, 9, 885-896.	10.7	63
83	A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults. BMC Pulmonary Medicine, 2016, 16, 77.	2.0	62
84	ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, 21, 691.	1.6	62
85	Risk factors for Clostridium difficile infection in hospitalized patients with community-acquired pneumonia. Journal of Infection, 2016, 73, 45-53.	3.3	60
86	Role of cephalosporins in the era ofClostridium difficileinfection. Journal of Antimicrobial Chemotherapy, 2017, 72, 1-18.	3.0	60
87	The heterogeneity of systemic inflammation in bronchiectasis. Respiratory Medicine, 2017, 127, 33-39.	2.9	58
88	Admission D-dimer Can Identify Low-Risk Patients With Community-Acquired Pneumonia. Annals of Emergency Medicine, 2009, 53, 633-638.	0.6	57
89	Distinct â€œImmunoallertypesâ€•of Disease and High Frequencies of Sensitization in Nonâ€“Cystic Fibrosis Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 842-853.	5.6	57
90	A membrane-depolarizing toxin substrate of the Staphylococcus aureus type VII secretion system mediates intraspecies competition. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 20836-20847.	7.1	57

#	Article	IF	Citations
91	Cardiovascular disease as a complication of community-acquired pneumonia. Current Opinion in Pulmonary Medicine, 2016, 22, 212-218.	2.6	56
92	Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis. Cytokine, 2016, 88, 267-273.	3.2	54
93	The economic burden of bronchiectasis â€“ known and unknown: a systematic review. BMC Pulmonary Medicine, 2019, 19, 54.	2.0	54
94	Same meat, different gravy: ignore the new names of mycobacteria. European Respiratory Journal, 2019, 54, 1900795.	6.7	54
95	Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice. Npj Primary Care Respiratory Medicine, 2017, 27, 43.	2.6	53
96	Estimates of the ongoing need for social distancing and control measures post-â€œlockdownâ€•from trajectories of COVID-19 cases and mortality. European Respiratory Journal, 2020, 56, 2001483.	6.7	53
97	Macrolide antibiotics for bronchiectasis. The Cochrane Library, 2018, 2018, CD012406.	2.8	52
98	Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic. Journal of Antimicrobial Chemotherapy, 2010, 65, 608-618.	3.0	51
99	Global impact of bronchiectasis and cystic fibrosis. Breathe, 2016, 12, 222-235.	1.3	51
100	A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and riskÂofÂexacerbation. European Respiratory Journal, 2019, 53, 1900303.	6.7	50
101	Community-acquired pneumonia in the United Kingdom: a call to action. Pneumonia (Nathan Qld), 2017, 9, 15.	6.1	48
102	RESPIRE: breathing new life into bronchiectasis. European Respiratory Journal, 2018, 51, 1702444.	6.7	46
103	A comprehensive approach to lung function in bronchiectasis. Respiratory Medicine, 2018, 145, 120-129.	2.9	46
104	Safety and efficacy of CURB65-guided antibiotic therapy in community-acquired pneumonia. Journal of Antimicrobial Chemotherapy, 2011, 66, 416-423.	3.0	45
105	The BRICS (Bronchiectasis Radiologically Indexed CT Score). Chest, 2018, 153, 1177-1186.	0.8	44
106	Economic burden of bronchiectasis in Germany. European Respiratory Journal, 2019, 53, 1802033.	6.7	44
107	Blood neutrophil counts are associated with exacerbation frequency and mortality in COPD. Respiratory Research, 2020, 21, 166.	3.6	44
108	A high-risk airway mycobiome is associated with frequent exacerbation and mortality in COPD. European Respiratory Journal, 2021, 57, 2002050.	6.7	44

#	Article	IF	Citations
109	Neutrophil extracellular traps in chronic lung disease: implications for pathogenesis and therapy. European Respiratory Review, 2022, 31, 210241.	7.1	44
110	Secreted mucins and airway bacterial colonization in nonâ€‹<scp>CF</scp> bronchiectasis. Respirology, 2015, 20, 1082-1088.	2.3	43
111	Antimicrobial peptides, disease severity and exacerbations in bronchiectasis. Thorax, 2019, 74, 835-842.	5.6	43
112	The impact of acute air pollution fluctuations on bronchiectasis pulmonary exacerbation: a case-crossover analysis. European Respiratory Journal, 2018, 52, 1702557.	6.7	42
113	Pregnancy Zone Protein Is Associated with Airway Infection, Neutrophil Extracellular Trap Formation, and Disease Severity in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 992-1001.	5.6	42
114	The immunomodulatory effects of macrolide antibiotics in respiratory disease. Pulmonary Pharmacology and Therapeutics, 2021, 71, 102095.	2.6	41
115	COPD and Bronchiectasis: Phenotype, Endotype or Co-morbidity?. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2014, 11, 603-604.	1.6	40
116	Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis. Respiratory Research, 2014, 15, 27.	3.6	39
117	British Thoracic Society guideline for bronchiectasis in adults. BMJ Open Respiratory Research, 2018, 5, e000348.	3.0	37
118	Sputum neutrophil elastase associates with microbiota and Pseudomonas aeruginosa in bronchiectasis. European Respiratory Journal, 2020, 56, 2000769.	6.7	37
119	Pulmonary arterial pulse pressure and mortality in pulmonary arterial hypertension. Respiratory Medicine, 2007, 101, 2495-2501.	2.9	35
120	A multidisciplinary intervention to reduce antibiotic duration in lower respiratory tract infections. Journal of Antimicrobial Chemotherapy, 2014, 69, 515-518.	3.0	34
121	The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC): experiences from a successful ERS Clinical Research Collaboration. Breathe, 2017, 13, 180-192.	1.3	34
122	ICU admission and severity assessment in community-acquired pneumonia. Critical Care, 2009, 13, 156.	5.8	33
123	<scp>Pseudomonas aeruginosa</scp> resistance patterns and clinical outcomes in hospitalized exacerbations of COPD. Respirology, 2016, 21, 1235-1242.	2.3	33
124	Quality standards for the management of bronchiectasis in Italy: a national audit. European Respiratory Journal, 2016, 48, 244-248.	6.7	33
125	The Impact of the COVID-19 Pandemic on Exacerbations and Symptoms in Bronchiectasis: A Prospective Study. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 857-859.	5.6	33
126	Raising awareness of bronchiectasis in primary care: overview of diagnosis and management strategies in adults. Npj Primary Care Respiratory Medicine, 2017, 27, 18.	2.6	32

#	Article	IF	Citations
127	Just breathe: a review of sex and gender in chronic lung disease. European Respiratory Review, 2022, 31, 210111.	7.1	32
128	A Randomized Controlled Trial of Atorvastatin in Patients With Bronchiectasis Infected With Pseudomonas Aeruginosa. Chest, 2017, 152, 368-378.	0.8	31
129	Bronchiectasis: an emerging global epidemic. BMC Pulmonary Medicine, 2018, 18, 76.	2.0	30
130	Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 Journal, 2020, 56, 2000110.	6.7	30
131	Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study. European Respiratory Journal, 2021, 57, 2001451.	6.7	30
132	Characteristics of bronchiectasis in Korea: First data from the Korean Multicentre Bronchiectasis Audit and Research Collaboration registry and comparison with other international registries. Respirology, 2021, 26, 619-621.	2.3	30
133	Severity assessment scores to guide empirical use of antibiotics in community acquired pneumonia. Lancet Respiratory Medicine,the, 2013, 1, 653-662.	10.7	29
134	Outcomes in patients with community-acquired pneumonia admitted to the intensive care unit. Respiratory Medicine, 2015, 109, 743-750.	2.9	29
135	Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. Respiratory Research, 2020, 21, 240.	3.6	29
136	Endotyping Chronic Obstructive Pulmonary Disease, Bronchiectasis, and the â€œChronic Obstructive Pulmonary Diseaseâ€“Bronchiectasis Associationâ€• American Journal of Respiratory and Critical Care Medicine, 2022, 206, 417-426.	5.6	29
137	Factors associated with severe illness in pandemic 2009 influenza a (H1N1) infection: Implications for triage in primary and secondary care. Journal of Infection, 2011, 63, 243-251.	3.3	28
138	Reclaiming the name â€˜bronchiectasisâ€™. Thorax, 2015, 70, 399-400.	5.6	28
139	Characterization of bronchiectasis in the elderly. Respiratory Medicine, 2016, 119, 13-19.	2.9	28
140	Genetic mannose binding lectin deficiency is associated with airway microbiota diversity and reduced exacerbation frequency in COPD. Thorax, 2018, 73, 510-518.	5.6	28
141	How to Process Sputum Samples and Extract Bacterial DNA for Microbiota Analysis. International Journal of Molecular Sciences, 2018, 19, 3256.	4.1	28
142	â€œThe missing ingredientâ€• the patient perspective of health related quality of life in bronchiectasis: a qualitative study. BMC Pulmonary Medicine, 2018, 18, 81.	2.0	28
143	Clinical and research priorities for children and young people with bronchiectasis: an international roadmap. ERJ Open Research, 2021, 7, 00122-2021.	2.6	28
144	The association between SARS-CoV-2 RT-PCR cycle threshold and mortality in a community cohort. European Respiratory Journal, 2021, 58, 2100360.	6.7	28

#	Article	IF	Citations
145	Diagnostic challenges of bronchiectasis. Respiratory Medicine, 2016, 116, 70-77.	2.9	27
146	The generalizability of bronchiectasis randomized controlled trials: A multicentre cohort study. Respiratory Medicine, 2016, 112, 51-58.	2.9	27
147	Why, when and how to investigate primary ciliary dyskinesia in adult patients with bronchiectasis. Multidisciplinary Respiratory Medicine, 2018, 13, 26.	1.5	27
148	Bronchiectasis: Phenotyping a Complex Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, 14, S12-S18.	1.6	26
149	The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) ERS Clinical Research Collaboration. European Respiratory Journal, 2018, 52, 1802074.	6.7	26
150	Bronchiectasis: a case-based approach to investigation and management. European Respiratory Review, 2018, 27, 180016.	7.1	26
151	International Perspective on the New 2019 American Thoracic Society/Infectious Diseases Society of America Community-Acquired Pneumonia Guideline. Chest, 2020, 158, 1912-1918.	0.8	26
152	Validation of the COPD Assessment Test (CAT) as an Outcome Measure in Bronchiectasis. Chest, 2020, 157, 815-823.	0.8	25
153	Relationship between Symptoms, Exacerbations, and Treatment Response in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1499-1507.	5.6	25
154	Neutrophil dysfunction in bronchiectasis: an emerging role for immunometabolism. European Respiratory Journal, 2021, 58, 2003157.	6.7	25
155	The protective effect of SARS-CoV-2 antibodies in Scottish healthcare workers. ERJ Open Research, 2021, 7, 00080-2021.	2.6	24
156	Right ventricular dilation on CT pulmonary angiogram independently predicts mortality in pulmonary embolism. Respiratory Medicine, 2010, 104, 1057-1062.	2.9	23
157	Cross-infection risk in patients with bronchiectasis: a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network. European Respiratory Journal, 2018, 51, 1701937.	6.7	23
158	Respiratory physiotherapy in the bronchiectasis guidelines: is there a loud voice we are yet to hear?. European Respiratory Journal, 2019, 54, 1901610.	6.7	23
159	Assessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD). Respiratory Research, 2018, 19, 63.	3.6	22
160	Inhaled aztreonam improves symptoms of cough and sputum production in patients with bronchiectasis: a post hoc analysis of the AIR-BX studies. European Respiratory Journal, 2020, 56, 2000608.	6.7	22
161	Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. European Respiratory Journal, 2022, 60, 2200803.	6.7	22
162	Can we use severity assessment tools to increase outpatient management of community-acquired pneumonia?. European Journal of Internal Medicine, 2012, 23, 398-406.	2.2	21

#	Article	IF	Citations
163	A prospective cohort study of the use of domiciliary intravenous antibiotics in bronchiectasis. Npj Primary Care Respiratory Medicine, 2014, 24, 14090.	2.6	21
164	Identification of Pseudomonas aeruginosa and airway bacterial colonization by an electronic nose in bronchiectasis. Respiratory Medicine, 2018, 136, 111-117.	2.9	21
165	A systematic review of pharmacotherapeutic clinical trial end-points for bronchiectasis in adults. European Respiratory Review, 2019, 28, 180108.	7.1	21
166	Heterogeneity of treatment response in bronchiectasis clinical trials. European Respiratory Journal, 2022, 59, 2100777.	6.7	21
167	No Strong Relationship Between Components of the Lectin Pathway of Complement and Susceptibility to Pulmonary Tuberculosis. Inflammation, 2015, 38, 1731-1737.	3.8	20
168	Challenges in the development of new therapies for bronchiectasis. Expert Opinion on Pharmacotherapy, 2015, 16, 833-850.	1.8	20
169	Corticosteroids for community-acquired pneumonia: a critical view of the evidence. European Respiratory Journal, 2016, 48, 984-986.	6.7	20
170	Patient participation in ERS guidelines and research projects: the EMBARC experience. Breathe, 2017, 13, 194-207.	1.3	20
171	Personalised anti-inflammatory therapy for bronchiectasis and cystic fibrosis: selecting patients for controlled trials of neutrophil elastase inhibition. ERJ Open Research, 2019, 5, 00252-2018.	2.6	20
172	Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review. Respiratory Research, 2019, 20, 242.	3.6	20
173	The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European Respiratory Society living guideline. European Respiratory Review, 2021, 30, 210171.	7.1	20
174	Airway Mucin 2 Is Decreased in Patients with Severe Chronic Obstructive Pulmonary Disease with Bacterial Colonization. Annals of the American Thoracic Society, 2016, 13, 636-642.	3.2	19
175	CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin. ERJ Open Research, 2020, 6, 00583-2020.	2.6	19
176	Utility of routine screening for alpha-1 antitrypsin deficiency in patients with bronchiectasis. Thorax, 2020, 75, 592-593.	5.6	19
177	ROSE: radiology, obstruction, symptoms and exposure â€“ a Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working Group. ERJ Open Research, 2021, 7, 00399-2021.	2.6	19
178	Anti-Pseudomonas aeruginosa IgG antibodies and chronic airway infection in bronchiectasis. Respiratory Medicine, 2017, 128, 1-6.	2.9	18
179	A Cluster Analysis of Bronchiectasis Patients Based on the Airway Immune Profile. Chest, 2021, 159, 1758-1767.	0.8	18
180	Inhaled Corticosteroids and the Lung Microbiome in COPD. Biomedicines, 2021, 9, 1312.	3.2	18

#	Article	IF	Citations
181	Clinical endotypes of exacerbation are associated with differences in microbial composition and diversity in COPD. European Respiratory Journal, 2020, 56, 2000391.	6.7	18
182	Treating Neutrophilic Inflammation in Airways Diseases. Archivos De Bronconeumologia, 2022, 58, 463-465.	0.8	18
183	Bronchiectasis and COPD Overlap. Chest, 2017, 151, 1204-1206.	0.8	17
184	New Insights Into the Epidemiology of Bronchiectasis. Chest, 2018, 154, 1272-1273.	0.8	17
185	Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report. Annals of the American Thoracic Society, 2021, 18, 1087-1097.	3.2	17
186	Pathophysiology of Bronchiectasis. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 499-512.	2.1	17
187	Defining severity in non-cystic fibrosis bronchiectasis. Expert Review of Respiratory Medicine, 2014, 8, 249-262.	2.5	16
188	Evaluation of active neutrophil elastase in sputum of bronchiectasis and cystic fibrosis patients: A comparison among different techniques. Pulmonary Pharmacology and Therapeutics, 2019, 59, 101856.	2.6	16
189	Pulmonary rehabilitation after exacerbation of bronchiectasis: a pilot randomized controlled trial. BMC Pulmonary Medicine, 2019, 19, 85.	2.0	16
190	Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey. Clinical Infectious Diseases, 2021, 73, e256-e259.	5.8	16
191	Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections. European Respiratory Review, 2021, 30, 210010.	7.1	16
192	Joint patient and clinician priority setting to identify 10 key research questions regarding the long-term sequelae of COVID-19. Thorax, 2022, 77, 717-720.	5.6	16
193	Increased Chitotriosidase Is Associated With Aspergillus and Frequent Exacerbations in South-East Asian Patients With Bronchiectasis. Chest, 2020, 158, 512-522.	0.8	15
194	Sputum neutrophil elastase in bronchiectasis: a Southern European cohort study. European Respiratory Journal, 2020, 56, 2001702.	6.7	15
195	Respiratory Mycoses in COPD and Bronchiectasis. Mycopathologia, 2021, 186, 623-638.	3.1	15
196	Serum Desmosine Is Associated with Long-Term All-Cause and Cardiovascular Mortality in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 897-899.	5.6	14
197	Validation of the Bronchiectasis Impact Measure (BIM): a novel patient-reported outcome measure. European Respiratory Journal, 2021, 57, 2003156.	6.7	14
198	Psychometrics of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis. European Respiratory Journal, 2021, 58, 2100025.	6.7	13

#	Article	IF	Citations
199	Using cluster analysis of cytokines to identify patterns of inflammation in hospitalized patients with community-acquired pneumonia: a pilot study.. The University of Louisville Journal of Respiratory Infections, 2017, 1, 3-11.	0.0	13
200	Empirical Coverage of Methicillin-ResistantStaphylococcus aureusin Community-Acquired Pneumonia: Those Who Do Not Remember the Past Are Doomed to Repeat It. Clinical Infectious Diseases, 2016, 63, 1145-1146.	5.8	12
201	Clinical and financial burden of hospitalised community-acquired pneumonia in patients with selected underlying comorbidities in England. BMJ Open Respiratory Research, 2020, 7, e000703.	3.0	12
202	Identifying severe community-acquired pneumonia: moving beyond mortality. Thorax, 2015, 70, 515-516.	5.6	11
203	Macrolide resistance in Pseudomonas aeruginosa: implications for practice. European Respiratory Journal, 2017, 49, 1700689.	6.7	11
204	Oral versus inhaled antibiotics for bronchiectasis. The Cochrane Library, 2018, 3, CD012579.	2.8	11
205	Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia. Respiratory Medicine, 2018, 140, 115-121.	2.9	11
206	Bronchiectasis insanity: Doing the same thing over and over again and expecting different results?. F1000Research, 2019, 8, 293.	1.6	11
207	Drive-through testing for SARS-CoV-2 in symptomatic health and social care workers and household members: an observational cohort study. Thorax, 2020, 75, 1109-1111.	5.6	11
208	Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST). Respiratory Research, 2020, 21, 18.	3.6	11
209	Bronchiectasis and inhaled tobramycin: A literature review. Respiratory Medicine, 2022, 192, 106728.	2.9	11
210	The Modern Diagnostic Approach to Community-Acquired Pneumonia in Adults. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 876-885.	2.1	10
211	Investigating the Etiology of Bronchiectasis: You Do Not Find What You Do Not Look For. Respiration, 2017, 93, 228-229.	2.6	10
212	Profile of the ProAxsis active neutrophil elastase immunoassay for precision medicine in chronic respiratory disease. Expert Review of Molecular Diagnostics, 2017, 17, 875-884.	3.1	10
213	The effect of changes to GOLD severity stage on long term morbidity and mortality in COPD. Respiratory Research, 2018, 19, 249.	3.6	10
214	The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol. Multidisciplinary Respiratory Medicine, 2018, 13, 33.	1.5	10
215	Severe Paediatric Asthma Collaborative in Europe (SPACE): protocol for a European registry. Breathe, 2018, 14, 93-98.	1.3	10
216	Is bronchiectasis really a disease?. European Respiratory Review, 2020, 29, 190051.	7.1	10

#	Article	IF	Citations
217	Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADOÂ® Trials. Advances in Therapy, 2021, 38, 579-593.	2.9	10
218	Sputum colour in nonâ€‹<scp>CF</scp> bronchiectasis: The original neutrophil biomarker. Respirology, 2014, 19, 153-154.	2.3	9
219	10â€...years since TORCH: shining a new light on the risks of inhaled corticosteroids in COPD. European Respiratory Journal, 2017, 50, 1701582.	6.7	9
220	High endocan levels are associated with the need for mechanical ventilation among patients with severe sepsis. European Respiratory Journal, 2017, 50, 1700013.	6.7	9
221	The past decade in bench research into pulmonary infectious diseases: <scp>W</scp>hat do clinicians need to know?. Respirology, 2017, 22, 1062-1072.	2.3	9
222	Cystic fibrosis lung disease and bronchiectasis. Lancet Respiratory Medicine,the, 2020, 8, 12-14.	10.7	9
223	Characteristics and outcomes of health and social care workers testing positive for SARS-CoV-2 in the Tayside region of Scotland. European Respiratory Journal, 2020, 56, 2002568.	6.7	9
224	European Respiratory Society International Congress, Madrid, 2019: nontuberculous mycobacterial pulmonary disease highlights. ERJ Open Research, 2020, 6, 00317-2020.	2.6	9
225	Development of Drugs for Nontuberculous Mycobacterial Disease. Chest, 2021, 159, 537-543.	0.8	9
226	Precision medicine inÂbronchiectasis. Breathe, 2021, 17, 210119.	1.3	9
227	Serum Ficolin-2 in Hospitalised Patients with Community-Acquired Pneumonia. Inflammation, 2014, 37, 1635-1641.	3.8	8
228	Chromogranin A levels and mortality in patients with severe sepsis. Biomarkers, 2015, 20, 171-176.	1.9	8
229	New therapies for the prevention and treatment of exacerbations of bronchiectasis. Current Opinion in Pulmonary Medicine, 2017, 23, 218-224.	2.6	8
230	Continuous versus intermittent antibiotics for bronchiectasis. The Cochrane Library, 2018, 2018, CD012733.	2.8	8
231	Treatment to prevent exacerbations in bronchiectasis: macrolides as first line?. European Respiratory Journal, 2019, 54, 1901213.	6.7	8
232	Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1). Pulmonary Pharmacology and Therapeutics, 2019, 58, 101834.	2.6	8
233	Rewiring the Immune Response in COVID-19. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 784-786.	5.6	8
234	Managing and preventing exacerbation of bronchiectasis. Current Opinion in Infectious Diseases, 2020, 33, 189-196.	3.1	8

#	Article	IF	Citations
235	High Frequency of Allergic Bronchopulmonary Aspergillosis in Bronchiectasis-COPD Overlap. Chest, 2022, 161, 40-53.	0.8	8
236	What is important for people with nontuberculous mycobacterial disease? An EMBARC-ELF patient survey. ERJ Open Research, 2021, 7, 00807-2020.	2.6	8
237	Sputum Proteomics in Nontuberculous Mycobacterial Lung Disease. Chest, 2022, 161, 1180-1191.	0.8	8
238	Cardiovascular outcomes in patients with chronic kidney disease and COVID-19: a multi-regional data-linkage study. European Respiratory Journal, 2022, 60, 2103168.	6.7	8
239	International consensus statement on quality standards for managing children/adolescents with bronchiectasis from the ERS CRC Child-BEAR-Net. European Respiratory Journal, 2022, 59, 2200264.	6.7	8
240	Investigation of "non-responding" presumed lower respiratory tract infection in primary care. BMJ: British Medical Journal, 2011, 343, d5840-d5840.	2.3	7
241	Year in review 2016: Respiratory infections, acute respiratory distress syndrome, pleural diseases, lung cancer and interventional pulmonology. Respirology, 2017, 22, 602-611.	2.3	7
242	POINT: Should an Attempt Be Made to Withdraw Inhaled Corticosteroids in All Patients With Stable GOLD 3 (30%Ââ‰ÂFEV1Â< 50% Predicted) COPD? Yes. Chest, 2018, 153, 778-782.	0.8	7
243	Macrolides, mucoactive drugs and adherence for the management of bronchiectasis. European Respiratory Journal, 2018, 51, 1702033.	6.7	7
244	Bronchiectasis Exacerbations Are Heart-Breaking. Annals of the American Thoracic Society, 2018, 15, 301-303.	3.2	7
245	A 2 Ã— 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52â€‰weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trial. Trials, 2019, 20, 747.	1.6	7
246	Using Airway Clearance Techniques in Bronchiectasis. Chest, 2020, 158, 1298-1300.	0.8	6
247	Patientsâ€™ perspectives on Bronchiectasis: findings from a social media listening (SML) study. ERJ Open Research, 2021, 7, 00096-2021.	2.6	6
248	LTA4H rs2660845 association with montelukast response in early and late-onset asthma. PLoS ONE, 2021, 16, e0257396.	2.5	6
249	Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis. Annals of the American Thoracic Society, 2021, 18, 1316-1325.	3.2	6
250	Pandemic trials: evidence-based medicine on steroids. European Respiratory Journal, 2020, 56, 2004116.	6.7	6
251	Epidemiology of CAP in Europe. , 2014, , 1-12.		6
252	Microbial Dysbiosis after Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1184-1186.	5.6	5

#	Article	IF	Citations
253	Macrolide antibiotics for non-cystic fibrosis bronchiectasis. The Cochrane Library, 2016, , .	2.8	5
254	Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia. European Respiratory Journal, 2017, 50, 1602306.	6.7	5
255	Multiple breath washout in bronchiectasis clinical trials: is it feasible?. ERJ Open Research, 2020, 6, 00363-2019.	2.6	5
256	Counting the cost of bronchiectasis. Respirology, 2020, 25, 1223-1224.	2.3	5
257	Maximizing Adherence and Gaining New Information For Your Chronic Obstructive Pulmonary Disease (MAGNIFY COPD): Study Protocol for the Pragmatic, Cluster Randomized Trial Evaluating the Impact of Dual Bronchodilator with Add-On Sensor and Electronic Monitoring on Clinical Outcomes. Journal of Pragmatic and Observational Research, 2021, Volume 12, 25-35.	1.5	5
258	Bronchiectasis Guidelines-Recommendations Into Practice. Archivos De Bronconeumologia, 2019, 55, 286-288.	0.8	5
259	Bronchiectasis from 2012 to 2022. Clinics in Chest Medicine, 2022, 43, 1-6.	2.1	5
260	Budesonide and risk of pneumonia. Lancet, The, 2009, 374, 2050.	13.7	4
261	Bronchiectasis trials: losing the battle but winning the war?. Lancet Respiratory Medicine,the, 2014, 2, 679-681.	10.7	4
262	Parapneumonic effusions: epidemiology and predictors of pleural infection. Current Respiratory Care Reports, 2014, 3, 52-60.	0.6	4
263	Withdrawal of ICS treatment in primary care: A practical guide. Practice Nursing, 2017, 28, 22-27.	0.1	4
264	Get together to increase awareness in bronchiectasis: a report of the 2nd World Bronchiectasis Conference. Multidisciplinary Respiratory Medicine, 2018, 13, 28.	1.5	4
265	Recommendations for travelling with bronchiectasis: a joint ELF/EMBARC/ERN-Lung collaboration. ERJ Open Research, 2019, 5, 00113-2019.	2.6	4
266	Happy Birthday, Bronchiectasis: 200 Years of Targeting Mucus. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 639-640.	5.6	4
267	BronchUK: protocol for an observational cohort study and biobank in bronchiectasis. ERJ Open Research, 2021, 7, 00775-2020.	2.6	4
268	Exhaled volatile organic compounds and lung microbiome in COPD: a pilot randomised controlled trial. ERJ Open Research, 2021, 7, 00253-2021.	2.6	4
269	The heterogeneity of bronchiectasis patient characteristics, management and outcomes across Europe: Data from the EMBARC registry. , 2018, , .		4
270	Intermittent prophylactic antibiotics for bronchiectasis. The Cochrane Library, 2022, 2022, CD013254.	2.8	4

#	Article	IF	Citations
271	A Powerful New Severity Score for Communityâ€Acquired Pneumonia But Will Anyone Use It?. Clinical Infectious Diseases, 2008, 47, 1363-1363.	5.8	3
272	Community-Acquired Pneumonia: A Global Perspective. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 797-798.	2.1	3
273	Bronchiectasis Management. Chest, 2017, 152, 1097-1099.	0.8	3
274	Predicting outcomes in bronchiectasis. Pulmonology, 2018, 24, 146-148.	2.1	3
275	Rheumatoid arthritis-associated bronchiectasis â€“ Authors' reply. Lancet, The, 2019, 393, 2036.	13.7	3
276	The microbiome in bronchiectasis: Cutting a lung story short. Respirology, 2020, 25, 43-44.	2.3	3
277	The evolution of the European Respiratory Journal: weathering the publishing pandemic. European Respiratory Journal, 2021, 57, 2100084.	6.7	3
278	SPLUNC1 is a novel marker of disease severity and airway infection in bronchiectasis. European Respiratory Journal, 2021, 58, 2101840.	6.7	3
279	Severity assessment tools in CAP. , 2014, , 88-104.		3
280	Genetic and pharmacological relationship between P-glycoprotein and increased cardiovascular risk associated with clarithromycin prescription: An epidemiological and genomic population-based cohort study in Scotland, UK. PLoS Medicine, 2020, 17, e1003372.	8.4	3
281	Comparison of different sets of immunological tests to identify treatable immunodeficiencies in adult bronchiectasis patients. ERJ Open Research, 2022, 8, 00388-2021.	2.6	3
282	Bronchiectasis enters the inflammation era. Respirology, 2022, 27, 488-489.	2.3	3
283	Multiple-Breath Washout Outcome Measures in Adults with Bronchiectasis. Annals of the American Thoracic Society, 2022, 19, 1489-1497.	3.2	3
284	World Bronchiectasis Day 2022. European Respiratory Journal, 2022, 59, 2201249.	6.7	3
285	Middle East Respiratory Syndrome. Critical Care Medicine, 2015, 43, 1344-1346.	0.9	2
286	Old Drugs for Bad Bugsâ€”Aerosolized Antibiotics in Ventilator-Associated Pneumonia*. Critical Care Medicine, 2015, 43, 697-698.	0.9	2
287	Management of chronic airway diseases: What can we learn from real-life data?. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, 14, S1-S2.	1.6	2
288	Oral versus intravenous clarithromycin in moderate to severe community-acquired pneumonia: an observational study. Pneumonia (Nathan Qld), 2017, 9, 2.	6.1	2

#	Article	IF	Citations
289	Continuous versus intermittent antibiotics for non-cystic fibrosis bronchiectasis. The Cochrane Library, 2017, , .	2.8	2
290	The Elusive Hunt for a Reliable Biomarker in Community-acquired Pneumonia. Are We Searching for Something That Canâ€™t Exist?. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 300-302.	5.6	2
291	Withdrawal of inhaled corticosteroids in COPD. European Respiratory Journal, 2020, 56, 2001778.	6.7	2
292	Variability in airway inflammation, symptoms, lung function and reliever use in asthma: anti-inflammatory reliever hypothesis and STIFLE study design. ERJ Open Research, 2020, 6, 00333-2019.	2.6	2
293	Associations between ambient air pollutants and hospital admissions: more needs to be done. Environmental Science and Pollution Research, 2021, 28, 61848-61852.	5.3	2
294	Management of bronchiectasis in Europe: Data from the European bronchiectasis registry (EMBARC). , 2016, , .		2
295	Neutrophil Extracellular Traps are Increased in Severe Bronchiectasis and Reduced by Long-Term Azithromycin Treatment. SSRN Electronic Journal, 0, , .	0.4	2
296	The Role of Bacteria and Viruses in Chronic Obstructive Pulmonary Disease. Current Respiratory Medicine Reviews, 2014, 9, 360-371.	0.2	2
297	Less is more? Antibiotic treatment duration for exacerbations of bronchiectasis. European Respiratory Journal, 2021, 58, 2101416.	6.7	2
298	Author responseâ€”vitamin D deficiency and systemic inflammation in bronchiectasis. Thorax, 2013, 68, 679.2-679.	5.6	1
299	Critical Care Transition and Prevention of ICU Readmissions. Critical Care Medicine, 2014, 42, 216-217.	0.9	1
300	Reply to Corrao et al. Clinical Infectious Diseases, 2014, 58, 1197-1198.	5.8	1
301	Review of the British Thoracic Society Winter Meeting 2013, 4â€“6 December, London, UK. Thorax, 2014, 69, 378-382.	5.6	1
302	Reply to Livorsi and Eckerle. Clinical Infectious Diseases, 2014, 59, 610-611.	5.8	1
303	Doing science: how to get credit for your scientific work. Breathe, 2015, 11, 153-155.	1.3	1
304	Renal replacement therapy in Scottish critical care units: A national audit of practices. Journal of the Intensive Care Society, 2015, 16, 45-51.	2.2	1
305	Bronchiectasis in adults: epidemiology, assessment of severity and prognosis. Current Pulmonology Reports, 2015, 4, 142-151.	1.3	1
306	Community-acquired severity predictionâ€”what are we predicting and why?. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 173-174.	0.5	1

#	Article	IF	Citations
307	Reply: Measuring Airway Mucin 2 in Patients with Severe Chronic Obstructive Pulmonary Disease with Bacterial Colonization. Annals of the American Thoracic Society, 2016, 13, 2104-2105.	3.2	1
308	Clinical phenotypes in bronchiectasis: right on track to develop precision medicine in respiratory diseases. International Journal of Tuberculosis and Lung Disease, 2016, 20, 709-709.	1.2	1
309	Disbiosis microbiana en las bronquiectasias y la fibrosis quÃstica. Archivos De Bronconeumologia, 2017, 53, 471-472.	0.8	1
310	Oral versus inhaled antibiotics for non-cystic fibrosis bronchiectasis. The Cochrane Library, 2017, , .	2.8	1
311	Microbial Dysbiosis in Bronchiectasis and Cystic Fibrosis. Archivos De Bronconeumologia, 2017, 53, 471-472.	0.8	1
312	ERS syllabus for postgraduate training in respiratory infections: a guide for comprehensive training. Breathe, 2018, 14, 269-275.	1.3	1
313	A systematic review of clinical trial registration in major respiratory journals 2010â€“2018. European Respiratory Journal, 2018, 52, 1801491.	6.7	1
314	Bronchiectasis Guidelines-Recommendations Into Practice. Archivos De Bronconeumologia, 2019, 55, 286-288.	0.8	1
315	Phenotype characterization of non-cystic fibrosis bronchiectasis in India. , 2017, , .		1
316	Multidimensional severity assessment in bronchiectasis - An analysis of 7 European cohorts. , 2016, , .		1
317	What is the best technique to extract bacterial DNA from sputum?. , 2018, , .		1
318	Phenotypes and endotypes. , 0, , 133-152.		1
319	IL-6 trans-signalling: how Haemophilus surfs the NET to amplify inflammation in COPD. European Respiratory Journal, 2021, 58, 2102143.	6.7	1
320	Intermittent prophylactic antibiotics for bronchiectasis. The Cochrane Library, 0, , .	2.8	1
321	An 18 year data-linkage study on the association between air pollution and acute limb ischaemia. Vasa - European Journal of Vascular Medicine, 2021, 50, 462-467.	1.4	1
322	Providing answers to respiratory patients' questions during COVID-19. Breathe, 2020, 16, 200219.	1.3	1
323	The evolution of the European Respiratory Journal: adapting in an era of change. European Respiratory Journal, 2022, 59, 2200037.	6.7	1
324	Critical appraisal of international adult bronchiectasis guidelines using the AGREE II tool. European Journal of Internal Medicine, 2022, , .	2.2	1

#	Article	IF	Citations
325	Bronchiectasis: Advances in Diagnosis and Management. Clinics in Chest Medicine, 2022, 43, xiii.	2.1	1
326	Macrolides and Mortality in Severe Community-Acquired Pneumonia*. Critical Care Medicine, 2014, 42, 475-477.	0.9	0
327	Preventing Arterial Catheter-Associated Bloodstream Infections. Critical Care Medicine, 2014, 42, 1533-1534.	0.9	0
328	Empirical Antibiotic Treatment for Community-acquired Pneumonia. Clinical Pulmonary Medicine, 2015, 22, 192-198.	0.3	0
329	Bronchiectasis: working together for better evidence. Lancet Respiratory Medicine,the, 2015, 3, 915-917.	10.7	0
330	Additional important research priorities for bronchiectasis in China. European Respiratory Journal, 2017, 49, 1602317.	6.7	0
331	Rebuttal From Dr Chalmers. Chest, 2018, 153, 785-786.	0.8	0
332	Turning thirty: evolution but not revolution at the ERJ. European Respiratory Journal, 2018, 51, 1702594.	6.7	0
333	Circulating desmosine as a biomarker of azithromycin treatment response: a post hoc analysis of the COLUMBUS randomised controlled trial. ERJ Open Research, 2018, 4, 00136-2018.	2.6	0
334	The evolution of theEuropean Respiratory Journal: volume 2. European Respiratory Journal, 2019, 53, 1802459.	6.7	0
335	Response. Chest, 2019, 155, 1302-1303.	0.8	0
336	Reply: More on Causal Inference Studies. Annals of the American Thoracic Society, 2019, 16, 646-646.	3.2	0
337	A cuckoo COVID coincidence?. European Respiratory Journal, 2020, 56, 2003236.	6.7	0
338	The evolution of the European Respiratory Journal: ready for the new decade!. European Respiratory Journal, 2020, 55, 1902503.	6.7	0
339	Bronchiectasis: Advances in Diagnosis and Treatment. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 497-498.	2.1	0
340	Inhaled antibiotics in chronic airway infections. , 0, , 57-79.		0
341	Non-cystic fibrosis bronchiectasis: definition, severity and impact of pulmonary exacerbations. , 0, , 38-57.		0
342	Antibiotic stewardship in the hospital setting. , 0, , 127-149.		0

#	Article	IF	Citations
343	Providing answers to respiratory patients' questions during COVID-19. Breathe, 2020, 16, 200219.	1.3	0
344	Clinical trials during the COVID-19 pandemic: research design and lessons. , 2021, , 214-231.		0
345	Title is missing!. , 2020, 17, e1003372.		0
346	Title is missing!. , 2020, 17, e1003372.		0
347	Title is missing!. , 2020, 17, e1003372.		0
348	Title is missing!. , 2020, 17, e1003372.		0
349	Title is missing!. , 2020, 17, e1003372.		0